— Says reanalysis shows anti-amyloid drug is a winner for Alzheimer's disease
by Judy George, Senior Staff Writer, MedPage Today October 22, 2019
Aducanumab over an illustration of colorful brain synapses with the Biogen logo in the bottom right corner
Biogen surprised the Alzheimer's disease community this morning when it announced plans to pursue regulatory approval for aducanumab, its investigational monoclonal antibody targeting beta-amyloid protein in early Alzheimer's disease.
Earlier this year, Biogen and partner Eisai terminated their phase III trials of aducanumab after interim analyses indicated the drug was ineffective.
But today, Biogen said a "new analysis of larger dataset showed that aducanumab reduced clinical decline in patients with early Alzheimer's disease as measured by the pre-specified primary and secondary endpoints," and based on discussions with the FDA, the company plans to submit its application to the FDA in early 2020.
The EMERGE and ENGAGE trials of aducanumab were stopped in March based on a pre-specified futility analysis that relied on early data of 1,748 patients who completed the 18-month study period, the company explained. Since then, a larger dataset of 3,285 patients became available; of these, 2,066 patients completed the full 18 months of treatment.
A new analysis of this larger dataset showed a different outcome from what the futility analysis predicted. The EMERGE trial showed statistically significant results on the pre-specified primary endpoint of clinical decline from baseline in Clinical Dementia Rating-Sum of Boxes scores at 78 weeks of 23% versus placebo (P=0.01).
The ENGAGE trial did not meet its primary endpoint. Biogen said, however, that it "believes that data from a subset of ENGAGE support the findings from EMERGE," and the problem with ENGAGE was that fewer patients received a high dose of aducanumab because the study started earlier.
What this new data means is a question of controversy: while investors were positive this morning, skeptics voiced concerns over inconsistencies in the new data, both within the ENGAGE study and comparisons between the two trials.
The ENGAGE trial, for example, showed worse symptoms and faster decline in patients who received the high dose of the drug versus placebo. The low-dose group performed better than the high-dose group in some measures. And neither trial reported data in absolute terms that would shed light on the findings' clinical significance.
Biogen was also cagey about safety, saying only that the drug's adverse-event profile in the two trials was "consistent with previous studies of aducanumab," but provided no details for the newly enlarged high-dose groups.
"The bottom line is they ran two parallel trials, and one was positive and one was negative," said Ron Petersen, MD, PhD, of the Mayo Clinic, who has consulted for Biogen but was not a trial investigator. "The million dollar question is why."
Changing the ENGAGE study protocol allowed more patients who were APOE4 carriers to be allocated to the high-dose group, Petersen told MedPage Today. "When they analyzed the subgroup of patients in the failed study who had had adequate exposure to the high dose of the drug for an adequate period of time, those data looked like the data from the positive study," he said. "That's what they're hanging their hat on."
"Finally, we see something that's working for Alzheimer's," noted Zaven Khachaturian, PhD, editor-in-chief of Alzheimer's & Dementia.
The data so far "looks pretty impressive," but Biogen only released the "show-and-tell for investors" and not details, Khachaturian told MedPage Today. "If the findings hold, that would be great," he said. "Even if it works on a small subset of patients, it is good news. Given the heterogeneity of the disease, it would be unreasonable to expect that it would work on every Alzheimer's case."
But whether the FDA will require another study is unknown: "Typically, FDA requires two pivotal studies," Khachaturian said. "Given the fact that Alzheimer's is such a national problem, they might overlook that and go along with just the data from these trials."
Like other clinicians and researchers on Tuesday, Eric Reiman, MD, of Banner Health in Phoenix, expressed cautious optimism. "We need to see the data presented to better understand the full implications," Reiman told MedPage Today. "But this news provides a shot in arm at the right time for amyloid-focused research, giving hope to those currently impacted by this terrible disease as we actively explore implications for future prevention trials."
Biogen plans to present data from the trials at the Clinical Trials on Alzheimer's Disease meeting in December 2019.
If approved, aducanumab would become the first drug to reduce the clinical decline of Alzheimer's disease and the first to show that removing beta-amyloid burden led to better clinical outcomes.
Successful Trading is the art of minimizing long term risk and maximizing capital allocation.
Recent BIIB News
- Biogen Reports Progress on Corporate Responsibility Priorities • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA • PR Newswire (US) • 03/31/2024 11:30:00 PM
- New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy • GlobeNewswire Inc. • 03/06/2024 12:30:51 PM
- Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting • GlobeNewswire Inc. • 03/04/2024 09:15:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 12:54:07 AM
- Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP • GlobeNewswire Inc. • 02/23/2024 12:00:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/22/2024 03:12:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 02:39:56 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 02:36:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 02:33:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 02:31:36 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 02:29:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 02:28:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 02:27:09 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/21/2024 03:24:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 02:13:26 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 11:14:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 11:06:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 11:04:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 11:03:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 11:01:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 11:00:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 10:56:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 12:07:23 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 12:11:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM